BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Search i

Search help

  • Enter one or more search terms in the search field. Upper and lower case are not relevant.
  • As soon as you have entered three letters in the search field, various search words will be suggested from which you can choose one.
  • If you are searching for a certain group of words, put these words in double quotes. The hits will then contain the words in the order you entered, e.g. "medicines for children".
  • Multiple search terms can also be combined with the Boolean operators AND and OR. When using the operator AND, the results contain the intersection of all search terms. When using the operator OR, the hits contain one of the search terms or only individual search terms. The result set is therefore significantly larger. Please note that these operators must be written in capital letters.
  • If you receive a (too) large number of hits as a result of your search, you can narrow it down by using filters. These filter options appear to the left of the search results and are subdivided into:

    • category (e.g. safety of medicinal products, medical devices, code systems)
    • format (e.g. download, risk information, DHPCs)
    • time interval (e.g. last 30 days, older than ...)
  • Selected filters can be removed individually or all at once ("Show all results").
  • By default, search results are sorted by relevance, but they can also be sorted chronologically ("Latest entries first" or "Oldest entries first").

Enter search term

819 results

Results per page: 10 20 30

Rote-Hand-Brief on Cardioxane® PDF, 279KB, File is accessible Date: 18. July 2011 Topics: Pharmakovigilanz Type: Download

Active substance: dexrazoxane

Dear Doctor Letter (Rote-Hand-Brief) on Cardioxane® (dexrazoxane): Restricted indications PDF, 279KB, File is accessible Date: 18. July 2011 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: dexrazoxane

As part of an arbitration by the EMA in 2017, the contraindications for children and adolescents listed in this dear Doctor Letter were partially removed.

Dear Doctor Letter (Rote-Hand-Brief) on medicinal products containing pioglitazone (actos®, Competact®, Tandemact®): Increased incidence of bladder cancer PDF, 178KB, File is accessible Date: 10. June 2011 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: pioglitazone

Important safety information on the use of medicinal products containing pioglitazone.

Information Letter regarding Regranex® Gel (becaplermin): Discontinuation of distribution in Europe PDF, 336KB, File is accessible Date: 10. June 2011 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: becaplermin

According to information from the pharmaceutical manufacturer, the distribution of Regranex® Gel (becaplermin 0.01%) in Europe will be discontinued as of 30 June.

Rote-Hand-Brief on actos®, Competact® and Tandemact® PDF, 178KB, File is accessible Date: 10. June 2011 Topics: Pharmakovigilanz Type: Download

Active substance: pioglitazon

Information Letter on Regranex® PDF, 336KB, File is accessible Date: 10. June 2011 Topics: Pharmakovigilanz Type: Download

Active substance: becaplermin

Oral contraceptives containing drospirenone (e.g. Yasmin®) - Update of product information regarding the risk of venous thromboembolisms Date: 30. May 2011 Topics: Pharmakovigilanz Type: Risk information

Active substance: drospirenone

Epidemiological studies have shown that the risk of venous thromboembolic events (VTE) due to the use of combined oral contraceptives (COCs) containing drospirenone is greater than when taking COCs containing levonorgestrel (so-called second …

Oral administration of medicinal products containing buflomedil: EMA recommends suspension of marketing authorisation Date: 26. May 2011 Topics: Pharmakovigilanz Type: Risk information

Active substance: buflomedil

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended suspending the marketing authorisation for oral use of medicines containing buflomedil in EU Member States.

Information Letter on Anemet® 200 mg Tabletten PDF, 143KB, File is accessible Date: 26. April 2011 Topics: Pharmakovigilanz Type: Download

Active substance: dolasetrone

Information letter regarding Anemet® 200 mg tablets (dolasetron): Discontinuation of production PDF, 143KB, File is accessible Date: 26. April 2011 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: dolasetron

Due to the risk of arrhythmias in connection with the administration of Anemet® 200 mg tablets to adults for prevention and treatment of nausea and vomiting associated with cytostatic chemotherapy, the pharmaceutical manufacturer has renounced …